RAAS-modifying drugs

Balancing Accuracy and Practicality: Should RAAS-Modifying Drugs Be Withdrawn in Primary Aldosteronism Diagnosis?

This article examines the debate on whether RAAS-modifying antihypertensives should be stopped before testing for primary aldosteronism, weighing diagnostic accuracy against patient safety and feasibility.